28129238|t|Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery
28129238|a|Transfusions represent one of the main progresses of modern medicine. However, accumulating evidence supports that transfusions correlate with worse survival outcomes in patients affected by solid cancers. In the present study, we aimed to investigate the effects of perioperative blood transfusion in locally advanced cervical cancer. Data of consecutive patients affected by locally advanced cervical cancer scheduled to undergo neoadjuvant chemotherapy plus radical surgery were retrospectively searched to test the impact of perioperative transfusions on survival outcomes. Five- year survival outcomes were evaluated using Kaplan-Meier and Cox models. The study included 275 patients. Overall, 170 (62%) patients had blood transfusion. Via univariate analysis, we observed that transfusion correlated with an increased risk of developing recurrence (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.09-4.40; P = 0.02). Other factors associated with 5- year disease-free survival were noncomplete clinical response after neoadjuvant chemotherapy (HR, 2.99; 95% CI, 0.92-9.63; P = 0.06) and pathological (P = 0.03) response at neoadjuvant chemotherapy as well as parametrial (P = 0.004), vaginal (P < 0.001), and lymph node (P = 0.002) involvements. However, via multivariate analysis, only vaginal (HR, 3.07; 95% CI, 1.20-7.85; P = 0.01) and lymph node involvements (HR, 2.4; 95% CI, 1.00-6.06; P = 0.05) correlate with worse disease-free survival. No association with worse outcomes was observed for patients undergoing blood transfusion (HR, 2.71; 95% CI, 0.91-8.03; P = 0.07). Looking at factors influencing overall survival, we observed that lymph node status (P = 0.01) and vaginal involvement (P = 0.06) were independently associated with survival. The role of blood transfusions in increasing the risk of developing recurrence in LAAC patients treated by neoadjuvant chemotherapy plus radical surgery remains unclear; further prospective studies are warranted.
28129238	0	6	Impact	T080	C4049986
28129238	10	28	Blood Transfusions	T061	C0005841
28129238	32	40	Survival	T052	C0038952
28129238	44	51	Locally	T082	C1517927
28129238	52	60	Advanced	T080	C0205179
28129238	61	76	Cervical Cancer	T191	C4048328
28129238	77	85	Patients	T101	C0030705
28129238	97	121	Neoadjuvant Chemotherapy	T061	C4272610
28129238	127	142	Radical Surgery	T061	C0543467
28129238	143	155	Transfusions	T061	C0005841
28129238	182	192	progresses	T169	C1272688
28129238	196	211	modern medicine	T079	C0242324
28129238	235	243	evidence	T078	C3887511
28129238	258	270	transfusions	T061	C0005841
28129238	292	300	survival	T052	C0038952
28129238	301	309	outcomes	T080	C0085415
28129238	313	321	patients	T101	C0030705
28129238	322	330	affected	T169	C0392760
28129238	334	347	solid cancers	T191	C0006826
28129238	364	369	study	T062	C0008972
28129238	374	379	aimed	T078	C1947946
28129238	383	394	investigate	T169	C1292732
28129238	410	423	perioperative	T079	C1518988
28129238	424	441	blood transfusion	T061	C0005841
28129238	445	452	locally	T082	C1517927
28129238	453	461	advanced	T080	C0205179
28129238	462	477	cervical cancer	T191	C4048328
28129238	499	507	patients	T101	C0030705
28129238	508	516	affected	T169	C0392760
28129238	520	527	locally	T082	C1517927
28129238	528	536	advanced	T080	C0205179
28129238	537	552	cervical cancer	T191	C4048328
28129238	574	598	neoadjuvant chemotherapy	T061	C4272610
28129238	604	619	radical surgery	T061	C0543467
28129238	625	640	retrospectively	T062	C0035363
28129238	641	649	searched	T052	C1706202
28129238	653	657	test	T169	C0039593
28129238	662	668	impact	T080	C4049986
28129238	672	685	perioperative	T079	C1518988
28129238	686	698	transfusions	T061	C0005841
28129238	702	710	survival	T052	C0038952
28129238	711	719	outcomes	T080	C0085415
28129238	727	731	year	T079	C0439234
28129238	732	740	survival	T052	C0038952
28129238	741	749	outcomes	T080	C0085415
28129238	771	783	Kaplan-Meier	T062	C2827659
28129238	788	798	Cox models	T081,T170	C0010234
28129238	804	809	study	T062	C0008972
28129238	823	831	patients	T101	C0030705
28129238	852	860	patients	T101	C0030705
28129238	865	882	blood transfusion	T061	C0005841
28129238	888	907	univariate analysis	T062	C0683962
28129238	912	920	observed	T169	C1441672
28129238	926	937	transfusion	T061	C0005841
28129238	967	971	risk	T078	C0035647
28129238	975	985	developing	T169	C0332253
28129238	986	996	recurrence	T191	C1458156
28129238	998	1010	hazard ratio	T081	C2985465
28129238	1012	1014	HR	T081	C2985465
28129238	1026	1045	confidence interval	T081	C0009667
28129238	1047	1049	CI	T081	C0009667
28129238	1063	1064	P	T081	C0033204
28129238	1107	1111	year	T079	C0439234
28129238	1112	1133	disease-free survival	T081	C0242793
28129238	1139	1150	noncomplete	T033	C3272974
28129238	1151	1168	clinical response	T033	C4055223
28129238	1175	1199	neoadjuvant chemotherapy	T061	C4272610
28129238	1201	1203	HR	T081	C2985465
28129238	1215	1217	CI	T081	C0009667
28129238	1230	1231	P	T081	C0033204
28129238	1244	1256	pathological	T033	C4050242
28129238	1258	1259	P	T081	C0033204
28129238	1268	1276	response	T033	C4050242
28129238	1280	1304	neoadjuvant chemotherapy	T061	C4272610
28129238	1316	1327	parametrial	T029	C1518890
28129238	1329	1330	P	T081	C0033204
28129238	1341	1348	vaginal	T023	C0042232
28129238	1350	1351	P	T081	C0033204
28129238	1366	1376	lymph node	T023	C0024204
28129238	1378	1379	P	T081	C0033204
28129238	1416	1437	multivariate analysis	T081	C0026777
28129238	1444	1451	vaginal	T023	C0042232
28129238	1453	1455	HR	T081	C2985465
28129238	1467	1469	CI	T081	C0009667
28129238	1482	1483	P	T081	C0033204
28129238	1496	1506	lymph node	T023	C0024204
28129238	1521	1523	HR	T081	C2985465
28129238	1534	1536	CI	T081	C0009667
28129238	1549	1550	P	T081	C0033204
28129238	1549	1550	P	T081	C0033204
28129238	1580	1601	disease-free survival	T081	C0242793
28129238	1629	1637	outcomes	T080	C0085415
28129238	1642	1650	observed	T169	C1441672
28129238	1655	1663	patients	T101	C0030705
28129238	1675	1692	blood transfusion	T061	C0005841
28129238	1694	1696	HR	T081	C2985465
28129238	1708	1710	CI	T081	C0009667
28129238	1723	1724	P	T081	C0033204
28129238	1765	1781	overall survival	T081	C4086681
28129238	1786	1794	observed	T169	C1441672
28129238	1800	1810	lymph node	T023	C0024204
28129238	1819	1820	P	T081	C0033204
28129238	1833	1840	vaginal	T023	C0042232
28129238	1854	1855	P	T081	C0033204
28129238	1899	1907	survival	T052	C0038952
28129238	1921	1939	blood transfusions	T061	C0005841
28129238	1958	1962	risk	T078	C0035647
28129238	1966	1976	developing	T169	C0332253
28129238	1977	1987	recurrence	T191	C1458156
28129238	1991	1995	LAAC	T191	C4048328
28129238	1996	2004	patients	T101	C0030705
28129238	2005	2012	treated	T061	C0332293
28129238	2016	2040	neoadjuvant chemotherapy	T061	C4272610
28129238	2046	2061	radical surgery	T061	C0543467
28129238	2070	2077	unclear	T033	C3845108
28129238	2087	2106	prospective studies	T062	C0033522